{"id":482814,"date":"2021-04-27T16:33:11","date_gmt":"2021-04-27T20:33:11","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/affinia-therapeutics-to-present-new-data-and-updates-on-aav-platform-at-the-american-society-of-gene-and-cell-therapy-annual-meeting\/"},"modified":"2021-04-27T16:33:11","modified_gmt":"2021-04-27T20:33:11","slug":"affinia-therapeutics-to-present-new-data-and-updates-on-aav-platform-at-the-american-society-of-gene-and-cell-therapy-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/affinia-therapeutics-to-present-new-data-and-updates-on-aav-platform-at-the-american-society-of-gene-and-cell-therapy-annual-meeting\/","title":{"rendered":"Affinia Therapeutics to Present New Data and Updates on AAV Platform at the American Society of Gene and Cell Therapy Annual Meeting"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">WALTHAM, Mass., April  27, 2021  (GLOBE NEWSWIRE) &#8212; Affinia Therapeutics, an innovative gene therapy company with a proprietary platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies for rare and non-rare diseases, today announced an oral presentation and three digital posters have been accepted for presentation at the American Society of Gene and Cell Therapy (ASGCT) 24<sup>th<\/sup> Annual Meeting, taking place virtually May 11-14, 2021.<\/p>\n<p>The presentations will showcase Affinia Therapeutics\u2019 vectors, which have enhanced tropism for the central nervous system, safety such as liver de-targeting, and improved manufacturing yields. The data provides insight into the company\u2019s viral vector library of novel AAVs, its AAV ancestral sequence reconstruction platform, and the potential of this platform to broaden the reach of gene therapies. Details for the oral presentation and posters are as follows:<\/p>\n<p>\n        <strong>Oral Presentation<\/strong>\n      <\/p>\n<p>\n        <strong>Title:<\/strong> AAVX Resin Binding Site Identification Via Library Screening Analysis on Novel AAV Vectors <br \/><strong>Education Session Title: <\/strong>Downstream Process of Vector Manufacturing<br \/><strong>Date and Time:<\/strong> Thursday, May 13, 2021, 6:30-6:45 p.m. ET<br \/><strong>Room:<\/strong> Room 9<br \/><strong>Abstract Number:<\/strong> 170<\/p>\n<p>\n        <strong>Digital Posters <\/strong><\/p>\n<p>        <strong>Title:<\/strong> CSF Delivery of Anc80L65 in Nonhuman Primates Results in More Widespread Gene Transfer Throughout the Central Nervous System Compared to AAV9<br \/><strong>Date and Time:<\/strong> Tuesday, May 11, 2021, 8:00-10:00 a.m. ET<br \/><strong>Poster Session Title:<\/strong> AAV Vectors \u2013 Preclinical and Proof-of-Concept Studies<br \/><strong>Abstract Number:<\/strong> 362<\/p>\n<p>\n        <strong>Title:<\/strong> Network Analysis of Complex Novel AAV Vector Library Datasets for De-risking Gene Therapy Candidate Selection<br \/><strong>Date and Time:<\/strong> Tuesday, May 11, 2021, 8:00-10:00 a.m. ET<br \/><strong>Poster Session Title:<\/strong> AAV Vectors \u2013 Virology and Vectorology<br \/><strong>Abstract Number:<\/strong> 285<\/p>\n<p>\n        <strong>Title:<\/strong> AAVmod2, An AAV Capsid Engineered to Independently Detarget the Liver and Enhance Gene Delivery to Skeletal Muscle <br \/><strong>Date and Time:<\/strong> Tuesday, May 11, 2021, 8:00-10:00 a.m. ET<br \/><strong>Poster Session Title:<\/strong> AAV Vectors \u2013 Virology and Vectorology<br \/><strong>Abstract Number:<\/strong> 286<\/p>\n<p>Founded in 2019, Affinia Therapeutics\u2019 science originates from work done by Luk Vandenberghe, Ph.D., associate professor at Massachusetts Eye and Ear and Harvard Medical School and a co-inventor of AAV9. The Company recently expanded its state-of-the-art discovery laboratories in Waltham, Mass., to add process science, analytical development, and manufacturing pilot plant capabilities as it advances its programs into the clinic.<\/p>\n<p>\n        <strong>About Affinia Therapeutics<\/strong><br \/>\n        <br \/>Affinia Therapeutics\u2019 purpose is to develop gene therapies that can have a transformative impact on people affected by devastating rare and non-rare diseases. The Company\u2019s proprietary platform enables it to methodically engineer novel AAV vectors and regulatory elements to make gene therapies with potentially improved tissue tropism, cell specificity, safety, and yields. With its innovative science, the Company is working to broaden the reach of life-changing gene therapies to meaningful numbers of patients with an initial focus on central nervous system (CNS) and muscle diseases with significant unmet need.\u00a0For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OzrCoaPqqL7GRyDMjvvBeQT8fIC5gqsz4KgQbUEfkO3OVm2WXJAsgve_Zae7QEv8745iEsGjSw9nbC_gE7-B-WrAPuLaMsa0wNFhwdEC-d8epbGhV1THTgk_nCqoOwRX_xjUlmrJoubSnNuE2NzOG1Xohuc44FvGhQPNZQ3DF61bXS0NeCn5qPWfZeZBKOyMXN9-u1DdQc1SpwEBmdxPV42_heXLhrfd4nkEVRO25UA=\" rel=\"nofollow noopener\" target=\"_blank\">www.affiniatx.com<\/a>.<\/p>\n<p>\n        <strong>Affinia Therapeutics Contacts<\/strong>\n      <\/p>\n<p>\n        <strong>Investors: <\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ahfyPindQUG1ZgvWCW74sAQX3QIpDgKcxE_JRYPYgHPRGylcweeU-3Rk32tP_M4n-bomJOvnz_drR1d42S3dOVlZtL3PzF3QelDKpn8yEB0=\" rel=\"nofollow noopener\" target=\"_blank\">investors@affiniatx.com<\/a>\n      <\/p>\n<p>\n        <strong>Media: <\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MZS_ly7mJEKAiwHmmcMjGqgBeJCHlr9k9EzZsFfZbLCjZ9OFyqGSf5SBOvbYxV84dvL-aKvBIyCIlPO20NFVYoY_olb4nIVL5kLCnQuxzGE=\" rel=\"nofollow noopener\" target=\"_blank\">media@affiniatx.com<\/a>\n      <\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNDg2NCM0MTQyMjAxIzUwMDA3MDg4Ng==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/47615beb-2e97-4da3-a8f9-5b1aa859e0c2\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WALTHAM, Mass., April 27, 2021 (GLOBE NEWSWIRE) &#8212; Affinia Therapeutics, an innovative gene therapy company with a proprietary platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies for rare and non-rare diseases, today announced an oral presentation and three digital posters have been accepted for presentation at the American Society of Gene and Cell Therapy (ASGCT) 24th Annual Meeting, taking place virtually May 11-14, 2021. The presentations will showcase Affinia Therapeutics\u2019 vectors, which have enhanced tropism for the central nervous system, safety such as liver de-targeting, and improved manufacturing yields. The data provides insight into the company\u2019s viral vector library of novel AAVs, its AAV ancestral sequence reconstruction platform, and the potential of this platform to broaden the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/affinia-therapeutics-to-present-new-data-and-updates-on-aav-platform-at-the-american-society-of-gene-and-cell-therapy-annual-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Affinia Therapeutics to Present New Data and Updates on AAV Platform at the American Society of Gene and Cell Therapy Annual Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-482814","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Affinia Therapeutics to Present New Data and Updates on AAV Platform at the American Society of Gene and Cell Therapy Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/affinia-therapeutics-to-present-new-data-and-updates-on-aav-platform-at-the-american-society-of-gene-and-cell-therapy-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Affinia Therapeutics to Present New Data and Updates on AAV Platform at the American Society of Gene and Cell Therapy Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WALTHAM, Mass., April 27, 2021 (GLOBE NEWSWIRE) &#8212; Affinia Therapeutics, an innovative gene therapy company with a proprietary platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies for rare and non-rare diseases, today announced an oral presentation and three digital posters have been accepted for presentation at the American Society of Gene and Cell Therapy (ASGCT) 24th Annual Meeting, taking place virtually May 11-14, 2021. The presentations will showcase Affinia Therapeutics\u2019 vectors, which have enhanced tropism for the central nervous system, safety such as liver de-targeting, and improved manufacturing yields. The data provides insight into the company\u2019s viral vector library of novel AAVs, its AAV ancestral sequence reconstruction platform, and the potential of this platform to broaden the &hellip; Continue reading &quot;Affinia Therapeutics to Present New Data and Updates on AAV Platform at the American Society of Gene and Cell Therapy Annual Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/affinia-therapeutics-to-present-new-data-and-updates-on-aav-platform-at-the-american-society-of-gene-and-cell-therapy-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-27T20:33:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNDg2NCM0MTQyMjAxIzUwMDA3MDg4Ng==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affinia-therapeutics-to-present-new-data-and-updates-on-aav-platform-at-the-american-society-of-gene-and-cell-therapy-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affinia-therapeutics-to-present-new-data-and-updates-on-aav-platform-at-the-american-society-of-gene-and-cell-therapy-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Affinia Therapeutics to Present New Data and Updates on AAV Platform at the American Society of Gene and Cell Therapy Annual Meeting\",\"datePublished\":\"2021-04-27T20:33:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affinia-therapeutics-to-present-new-data-and-updates-on-aav-platform-at-the-american-society-of-gene-and-cell-therapy-annual-meeting\\\/\"},\"wordCount\":479,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affinia-therapeutics-to-present-new-data-and-updates-on-aav-platform-at-the-american-society-of-gene-and-cell-therapy-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyNDg2NCM0MTQyMjAxIzUwMDA3MDg4Ng==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affinia-therapeutics-to-present-new-data-and-updates-on-aav-platform-at-the-american-society-of-gene-and-cell-therapy-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affinia-therapeutics-to-present-new-data-and-updates-on-aav-platform-at-the-american-society-of-gene-and-cell-therapy-annual-meeting\\\/\",\"name\":\"Affinia Therapeutics to Present New Data and Updates on AAV Platform at the American Society of Gene and Cell Therapy Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affinia-therapeutics-to-present-new-data-and-updates-on-aav-platform-at-the-american-society-of-gene-and-cell-therapy-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affinia-therapeutics-to-present-new-data-and-updates-on-aav-platform-at-the-american-society-of-gene-and-cell-therapy-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyNDg2NCM0MTQyMjAxIzUwMDA3MDg4Ng==\",\"datePublished\":\"2021-04-27T20:33:11+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affinia-therapeutics-to-present-new-data-and-updates-on-aav-platform-at-the-american-society-of-gene-and-cell-therapy-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affinia-therapeutics-to-present-new-data-and-updates-on-aav-platform-at-the-american-society-of-gene-and-cell-therapy-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affinia-therapeutics-to-present-new-data-and-updates-on-aav-platform-at-the-american-society-of-gene-and-cell-therapy-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyNDg2NCM0MTQyMjAxIzUwMDA3MDg4Ng==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyNDg2NCM0MTQyMjAxIzUwMDA3MDg4Ng==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affinia-therapeutics-to-present-new-data-and-updates-on-aav-platform-at-the-american-society-of-gene-and-cell-therapy-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Affinia Therapeutics to Present New Data and Updates on AAV Platform at the American Society of Gene and Cell Therapy Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Affinia Therapeutics to Present New Data and Updates on AAV Platform at the American Society of Gene and Cell Therapy Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/affinia-therapeutics-to-present-new-data-and-updates-on-aav-platform-at-the-american-society-of-gene-and-cell-therapy-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Affinia Therapeutics to Present New Data and Updates on AAV Platform at the American Society of Gene and Cell Therapy Annual Meeting - Market Newsdesk","og_description":"WALTHAM, Mass., April 27, 2021 (GLOBE NEWSWIRE) &#8212; Affinia Therapeutics, an innovative gene therapy company with a proprietary platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies for rare and non-rare diseases, today announced an oral presentation and three digital posters have been accepted for presentation at the American Society of Gene and Cell Therapy (ASGCT) 24th Annual Meeting, taking place virtually May 11-14, 2021. The presentations will showcase Affinia Therapeutics\u2019 vectors, which have enhanced tropism for the central nervous system, safety such as liver de-targeting, and improved manufacturing yields. The data provides insight into the company\u2019s viral vector library of novel AAVs, its AAV ancestral sequence reconstruction platform, and the potential of this platform to broaden the &hellip; Continue reading \"Affinia Therapeutics to Present New Data and Updates on AAV Platform at the American Society of Gene and Cell Therapy Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/affinia-therapeutics-to-present-new-data-and-updates-on-aav-platform-at-the-american-society-of-gene-and-cell-therapy-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-27T20:33:11+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNDg2NCM0MTQyMjAxIzUwMDA3MDg4Ng==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affinia-therapeutics-to-present-new-data-and-updates-on-aav-platform-at-the-american-society-of-gene-and-cell-therapy-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affinia-therapeutics-to-present-new-data-and-updates-on-aav-platform-at-the-american-society-of-gene-and-cell-therapy-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Affinia Therapeutics to Present New Data and Updates on AAV Platform at the American Society of Gene and Cell Therapy Annual Meeting","datePublished":"2021-04-27T20:33:11+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affinia-therapeutics-to-present-new-data-and-updates-on-aav-platform-at-the-american-society-of-gene-and-cell-therapy-annual-meeting\/"},"wordCount":479,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affinia-therapeutics-to-present-new-data-and-updates-on-aav-platform-at-the-american-society-of-gene-and-cell-therapy-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNDg2NCM0MTQyMjAxIzUwMDA3MDg4Ng==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affinia-therapeutics-to-present-new-data-and-updates-on-aav-platform-at-the-american-society-of-gene-and-cell-therapy-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/affinia-therapeutics-to-present-new-data-and-updates-on-aav-platform-at-the-american-society-of-gene-and-cell-therapy-annual-meeting\/","name":"Affinia Therapeutics to Present New Data and Updates on AAV Platform at the American Society of Gene and Cell Therapy Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affinia-therapeutics-to-present-new-data-and-updates-on-aav-platform-at-the-american-society-of-gene-and-cell-therapy-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affinia-therapeutics-to-present-new-data-and-updates-on-aav-platform-at-the-american-society-of-gene-and-cell-therapy-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNDg2NCM0MTQyMjAxIzUwMDA3MDg4Ng==","datePublished":"2021-04-27T20:33:11+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affinia-therapeutics-to-present-new-data-and-updates-on-aav-platform-at-the-american-society-of-gene-and-cell-therapy-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/affinia-therapeutics-to-present-new-data-and-updates-on-aav-platform-at-the-american-society-of-gene-and-cell-therapy-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affinia-therapeutics-to-present-new-data-and-updates-on-aav-platform-at-the-american-society-of-gene-and-cell-therapy-annual-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNDg2NCM0MTQyMjAxIzUwMDA3MDg4Ng==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNDg2NCM0MTQyMjAxIzUwMDA3MDg4Ng=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affinia-therapeutics-to-present-new-data-and-updates-on-aav-platform-at-the-american-society-of-gene-and-cell-therapy-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Affinia Therapeutics to Present New Data and Updates on AAV Platform at the American Society of Gene and Cell Therapy Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/482814","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=482814"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/482814\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=482814"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=482814"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=482814"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}